Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-03-08
2009-10-06
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387100
Reexamination Certificate
active
07597890
ABSTRACT:
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.
REFERENCES:
patent: 6610508 (2003-08-01), Hentze et al.
patent: 6686147 (2004-02-01), Scanlan et al.
patent: 6783961 (2004-08-01), Edwards et al.
patent: 6943241 (2005-09-01), Isogai et al.
patent: 7115416 (2006-10-01), Edwards et al.
patent: 7205117 (2007-04-01), Robertson et al.
patent: 7214498 (2007-05-01), Nelson et al.
patent: 7368527 (2008-05-01), Rosen et al.
patent: 7402403 (2008-07-01), Robertson et al.
patent: 2003/0092009 (2003-05-01), Palm
patent: 2006/0014138 (2006-01-01), Chinnaiyan
patent: 1074617 (2001-02-01), None
patent: 1270724 (2003-01-01), None
patent: WO0218424 (2002-03-01), None
patent: WO 03/010199 (2003-02-01), None
patent: WO 03/064593 (2003-08-01), None
Hale et al., “Zinc α-2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer1” Clinical Cancer Research, Apr. 2001; 7(4): 846-53.
Zhong, et al. “Efficient Identification And User of Tumor-Associated Antibodies as Markers of Non-small Cell Lung Cancer” Chest 2004, vol. 125, pp. 105-106.
Hufton et al. “Serological antigen selection of phage displayed colorectal tumour cDNA libraries.” Biochemical Society Transactions. vol. 26, p. S5, entire document (1998).
Miller et al. “Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers.” Proteomics. vol. 3, pp. 56-63, p. 58 (2003).
Eisen et al. “Cluster analysis and display of genome-wide expression patterns.” Proceedings of the National Academy of Sciences USA. vol. 95, pp. 14863-14868 (1998).
Li et al. “Gene Assessment and Sample Classification for Gene Expression Data Using a Genetic Algorithm/k-nearest Neighbor Method.” Combinatorial Chemistry & High Throughput Screening. vol. 4, pp. 727-739 (2001).
Golub et al. “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring.” Science. vol. 286, pp. 531-537(1999).
Crescenzi and Giuliani. “The main biological determinants of tumor line taxonomy elucidated by a principal component analysis of microarray data.” FEBS Letters. vol. 507, pp. 114-118 (2001).
Denis and Green. “A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator.” Genes & Development. vol. 10, pp. 261-271 (1996).
Denis et al. “RING3 Kinase Transactivates Promoters of Cell Cycle Regulatory Genes through E2F.” Cell Growth & Differentiation. vol. 11, pp. 471-424 (2000).
Kanno et al. “Selective Recognition of Acetylated Histones by Bromodomain Proteins Visualized in Living Cells.” Molecular Cell. vol. 13, pp. 33-43 (2004).
Gingras et al. “Regulation of translation initiation by FRAP/mTOR.” Genes & Development. vol. 15, pp. 807-826 (2001).
Morino et al. “Eukaryotic Translation Initiation Factor 4E (eIF4E) Binding Site and the Middle One-Third of eIF4GI Constitute the Core Domain for Cap-Dependent Translation, and the C-Terminal One-Third Functions as a Modulatory Region.” Molecular and Cellular Biology. vol. 20, pp. 468-477 (2000).
Cromer et al. “Identification of genes associate with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis.” Oncogene. vol. 23, pp. 2484-2498 (2004).
Park et al. “Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.” Nature. vol. 15, No. 423 (6937), pp. 302-305 (2003).
Brass et al. “Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma.” Human Molecular Genetics. vol. 6, pp. 33-39 (1997).
Bauer et al. “Translation Initiation Factor eIF-4G Is Immunogenic, Overexposed, and Amplified in Patients with Squamous Cell Lung Carcinoma.” Cancer. vol. 92, pp. 822-829 (2001).
Bauer, C. et al. “Overexpression of the Eukaryotic Translation Initiation Factor 4G (EIF4G-1) in Squamous Cell Lung Carcinoma.” International Journal of Cancer. vol. 98, pp. 181-185 (2002).
Fukuchi-Shimogori et al. “Malignant Transformation by Overproduction of Translation Initiation Factor eIF4G.” Cancer Research. vol. 57, pp. 5041-5044 (1997).
Mazumder et al. “Regulated Release of L13a from the 60S Ribosomal Subunit as A Mechanism of Transcript-Specific Translational Control.” Cell. vol. 115, pp. 187-198 (2003).
Miura et al. “Laser Capture Microdissection and Microarray Expression Analysis of Lung Adenocarcinoma Reveals Tobacco Smoking- and Prognosis-related Molecular Profiles.” Cancer Research. vol. 62, pp. 3244-3250 (2002).
Racz et al. “Expression Analysis of Genes at 3q26-q27 Involved in Frequent Amplification in Squamous Cell Lung Carcinoma.” European Journal of Cancer. vol. 35, pp. 641-646 (1999).
Molofsky et al. “Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation.” Nature. vol. 425, pp. 962-967 (2003).
Singh and Figg. “Upregulation of the Androgen Receptor During Prostate Cancer Progression.” Cancer Biology and Therapy. vol. 3 pp. 284-285 (2004).
Taplin et al. “Androgen Receptor: A Key Molecule in the Progression of Prostate Cancer to Hormone Independence.” Journal of Cellular Biochemistry. vol. 91, pp. 483-490 (2004).
Liao and Witte. “Autoimmune anti-androgen-receptor antibodies in human serum.” Proceedings of the National Academy of Sciences USA. vol. 82, pp. 8345-8348 (1985).
Latulippe et al. “Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated with Metastatic Disease.” Cancer Research. vol. 62, pp. 4499-4506 (2002).
Luo et al. “Gene Expression Analysis of Prostate Cancers.” Molecular Carcinogenesis. vol. 33, pp. 25-35 (2002).
Luo et al. “Human Prostate Cancer and Benign Prostatic Hyperplasia: Molecular Dissection by Gene Expression Profiling.” Cancer Research. vol. 61, pp. 4683-4688 (2001).
Singh et al. “Gene expression correlates of clinical prostate cancer behavior.” Cancer Cell. vol. 1, pp. 203-209 (2002).
Welsh et al. “Analysis of Gene Expression Indentifies Candidate Markers and Pharmacological Targets in Prostate Cancer.” Cancer Research. vol. 61, pp. 5974-5978 (2001).
Bolstad et al. “A comparison of normalization methods for high density oligonucleotide array data based on variance and bias.” Bioinformatics. vol. 19, pp. 185-193 (2003).
Bo et al. “New Feature subset selection procedures for classification of expression profiles.” Genome Biology. vol. 3, No. 4, research0017.1-0017.11 (2002).
Rhodes et al. “Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.” Proceedings of the National Academy of Sciences USA. vol. 101, No. 25, pp. 9309-9314 (2004).
Rhodes et al. “ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform.” Neoplasia. vol. 6, No. 1, pp. 1-6 (2004).
Wang et al. “Autoantibody Signatures in Prostate Cancer.” New England Journal of Medicine. 353, No. 12, pp. 1224-1235 (2005).
Radmacher et al. “A Paradigm for Class Prediction Using Gene Expression Profiles.” Journal of Computational Biology. vol. 9, No. 3, pp. 505-511 (2002).
Tukey et al. “Tightening the Clinical Trial.” Controlled Clinical Trials. vol. 14, No. 4, pp. 266-285 (1993).
Kleijnen et al. “The hPLIC Proteins May Provide a Link between the Ubiquitination Machinery and the Proteasome.” Molecular Cell. vol. 6. No. 2, pp. 409-419 (2000).
Ma
Beer David
Chen Guoan
Chinnaiyan Arul
Wang Xiaoju
Casimir Jones S.C.
Helms Larry R.
Natarajan Meera
The Regents of the University of Michigan
LandOfFree
Methods and compositions for diagnosing lung cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for diagnosing lung cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for diagnosing lung cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134070